290 related articles for article (PubMed ID: 17473456)
1. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
[TBL] [Abstract][Full Text] [Related]
2. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.
Jayaraman R; Pilla Reddy V; Pasha MK; Wang H; Sangthongpitag K; Yeo P; Hu CY; Wu X; Xin L; Goh E; New LS; Ethirajulu K
Drug Metab Dispos; 2011 Dec; 39(12):2219-32. PubMed ID: 21873472
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
5. Metabolism and pharmacokinetics characterization of metarrestin in multiple species.
Padilha EC; Shah P; Wang AQ; Singleton MD; Hughes EA; Li D; Rice KA; Konrath KM; Patnaik S; Marugan J; Rudloff U; Xu X
Cancer Chemother Pharmacol; 2020 Apr; 85(4):805-816. PubMed ID: 32185484
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the pharmacokinetics and metabolism of a novel histone deacetylase inhibitor, KBH-A40, in rats.
Oh SJ; Lee K; Ryu J; Yu HE; Han G; Park SK; Kang JS; Kim HM; Kim YC
Xenobiotica; 2011 Feb; 41(2):155-63. PubMed ID: 21070143
[TBL] [Abstract][Full Text] [Related]
9. Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species.
Sandhu P; Andrews PA; Baker MP; Koeplinger KA; Soli ED; Miller T; Baillie TA
Drug Metab Lett; 2007 Apr; 1(2):153-61. PubMed ID: 19356036
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog.
Kamath AV; Chang M; Lee FY; Zhang Y; Marathe PH
Cancer Chemother Pharmacol; 2005 Aug; 56(2):145-53. PubMed ID: 15830240
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice.
Otaegui D; Rodríguez-Gascón A; Zubia A; Cossío FP; Pedraz JL
Cancer Chemother Pharmacol; 2009 Jun; 64(1):153-9. PubMed ID: 19002463
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic characterization of 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone, a novel 11β-hydroxysteroid dehydrogenase type 1 inhibitor in rats.
Zheng Z; Seo H; Kwak HJ; Kim KY; Ahn JH; Bae MA; Song JS
Arch Pharm Res; 2016 Apr; 39(4):492-498. PubMed ID: 26780247
[TBL] [Abstract][Full Text] [Related]
13. Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-species in vitro metabolism.
Bhamidipati R; Mujeeb S; Dravid PV; Khan AA; Singh SK; Rao YK; Mullangi R; Srinivas NR
Xenobiotica; 2005 Mar; 35(3):253-71. PubMed ID: 16019950
[TBL] [Abstract][Full Text] [Related]
14. Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties.
Yang Z; Zadjura LM; Marino AM; D'Arienzo CJ; Malinowski J; Gesenberg C; Lin PF; Colonno RJ; Wang T; Kadow JF; Meanwell NA; Hansel SB
J Pharm Sci; 2010 Apr; 99(4):2135-52. PubMed ID: 19780144
[TBL] [Abstract][Full Text] [Related]
15. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.
Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843
[TBL] [Abstract][Full Text] [Related]
16. In vitro drug metabolism and pharmacokinetics of a novel thiazolidinedione derivative, a potential anticancer compound.
S S; Vuppu S
J Pharm Biomed Anal; 2020 Feb; 179():113000. PubMed ID: 31787460
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics.
Gu Y; Wang J; Li K; Zhang L; Ren H; Guo L; Sai Y; Zhang W; Su W
Cancer Chemother Pharmacol; 2014 Jul; 74(1):95-115. PubMed ID: 24817647
[TBL] [Abstract][Full Text] [Related]
18. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor.
Pasha MK; Jayaraman R; Reddy VP; Yeo P; Goh E; Williams A; Goh KC; Kantharaj E
Drug Metab Lett; 2012 Mar; 6(1):33-42. PubMed ID: 22372550
[TBL] [Abstract][Full Text] [Related]
19. Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 - A potential oral treatment for tuberculosis.
Kour G; Kumar A; Singh PP; Sharma S; Bhagat A; Vishwakarma RA; Ahmed Z
Pulm Pharmacol Ther; 2016 Oct; 40():44-51. PubMed ID: 27457685
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.
Patel H; Giri P; Patel P; Singh S; Gupta L; Patel U; Modi N; Shah K; Jain MR; Srinivas NR; Patel P
Xenobiotica; 2018 Dec; 48(12):1268-1277. PubMed ID: 29224415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
